Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer.

Abstract

AIM:

To compare the efficacy and safety of triple therapy with omeprazole plus amoxycillin and clarithromycin vs. ranitidine bismuth citrate plus amoxycillin and clarithromycin in the treatment of Helicobacter pylori-associated duodenal ulcers.

METHODS:

Eighty-one patients with duodenal ulcers were randomized to the following treatments: 39 cases with amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 1 week plus omeprazole 20 mg b.d. for 2 weeks (omeprazole + amoxycillin + clarithromycin (OAC)), and 42 cases to the same regimen of amoxycillin and clarithromycin for 7 days plus ranitidine bismuth citrate 400 mg b.d. for 2 weeks (ranitidine bismuth citrate + amoxycillin + clarithromycin (RbAC)). Upper gastrointestinal endoscopy was performed together with a rapid urease test and histological examination of antral and corpus biopsy samples prior to treatment and 4 weeks after the end of therapy.

RESULTS:

Thirty-four patients in the OAC group and 38 in the RbAC group completed the treatment and 4-week follow-up. H. pylori was eradicated in 30 of 34 patients (88%) in the OAC group and in 32 of 38 patients (84%) in the RbAC group according to a per-protocol analysis (P = N.S.). Thirty-three (97%) patients treated with OAC and 36 (95%) treated with RbAC presented healed duodenal ulcers at 4 weeks (P = N.S.). On an intention-to-treat basis there was no difference in H. pylori eradication between the OAC (77%) and RbAC groups (76%); duodenal ulcer healing was achieved in 85 and 86% of patients in the OAC and RbAC groups, respectively (P = N.S.).

CONCLUSION:

The OAC and RbAC triple therapy regimens proved equally effective in both H. pylori eradication and in duodenal ulcer healing.

• Authors: F Catalano, R Catanzaro, C Bentivegna, A Brogna, G Condorelli, R Cipolla
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 12 Issue 1 Pg. 59-62 (Jan 1998) ISSN: 0269-2813 [Print] England
• PMID: 9692702 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Anti-Ulcer Agents
• Histamine H2 Antagonists
• Penicillins
• ranitidine bismuth citrate
• Amoxicillin
• Ranitidine
• Clarithromycin
• Omeprazole
• Bismuth

Topics

• Adult
• Aged
• Amoxicillin (administration & dosage, therapeutic use)
• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Bismuth (administration & dosage, therapeutic use)
• Clarithromycin (administration & dosage, therapeutic use)
• Clinical Protocols
• Drug Therapy, Combination
• Duodenal Ulcer (drug therapy, microbiology)
• Female
• Helicobacter pylori (drug effects)
• Histamine H2 Antagonists (administration & dosage, therapeutic use)
• Humans
• Male
• Middle Aged
• Omeprazole (administration & dosage, therapeutic use)
• Penicillins (administration & dosage, therapeutic use)
• Prospective Studies
• Ranitidine (administration & dosage, analogs & derivatives, therapeutic use)
• Single-Blind Method